A Biotech ETF Gets Its Groove Back

MarketsETF Trends

After struggling through one of its worst annual performances in several years in 2016, the SPDR S&P Biotech ETF (NYSEArca: XBI), the third-largest biotechnology exchange traded fund, is surging to start 2017. XBI, which is an equal-weight ETF with significant exposure to smaller biotechnology names, is up nearly 17% year-to-date and that could be a…Click to read more at ETFtrends.com.

Continue Reading Below